Yousif Capital Management LLC Sells 1,195 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Yousif Capital Management LLC lessened its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 2.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 49,454 shares of the medical research company’s stock after selling 1,195 shares during the quarter. Yousif Capital Management LLC’s holdings in NeoGenomics were worth $815,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of NEO. Fernwood Investment Management LLC raised its holdings in NeoGenomics by 1.0% in the 3rd quarter. Fernwood Investment Management LLC now owns 89,500 shares of the medical research company’s stock valued at $1,320,000 after buying an additional 900 shares during the last quarter. FMR LLC raised its stake in shares of NeoGenomics by 7.6% during the third quarter. FMR LLC now owns 13,255 shares of the medical research company’s stock valued at $196,000 after acquiring an additional 931 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of NeoGenomics by 42.3% during the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after purchasing an additional 987 shares during the period. KBC Group NV grew its stake in shares of NeoGenomics by 33.1% in the third quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock worth $67,000 after purchasing an additional 1,127 shares during the last quarter. Finally, Versant Capital Management Inc increased its holdings in NeoGenomics by 174.9% in the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 1,142 shares during the period. 98.50% of the stock is currently owned by institutional investors and hedge funds.

NeoGenomics Stock Up 3.7 %

NEO stock opened at $14.42 on Friday. The stock’s 50 day simple moving average is $15.70 and its 200 day simple moving average is $15.60. The company has a market cap of $1.85 billion, a P/E ratio of -23.64 and a beta of 1.23. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99. NeoGenomics, Inc. has a fifty-two week low of $12.13 and a fifty-two week high of $19.11.

Wall Street Analyst Weigh In

A number of research firms have commented on NEO. Jefferies Financial Group initiated coverage on NeoGenomics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price target on the stock. The Goldman Sachs Group decreased their target price on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Bank of America boosted their price target on shares of NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price objective on shares of NeoGenomics in a research report on Friday, January 10th. Finally, Benchmark lowered shares of NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $20.20.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.